American Capital Management Inc. Makes New $5.02 Million Investment in Haemonetics Corporation $HAE

Key Points

• American Capital Management acquired 66,915 Haemonetics shares worth approximately $5.02 million, representing about 0.15% of the company. Institutional investors collectively own 99.67% of Haemonetics.
• Haemonetics exceeded quarterly expectations, reporting $1.14 in EPS versus the $1.08 consensus and revenue of $339.38 million versus estimates of $327.86 million. Revenue increased 5.5% year over year.
• Analyst sentiment is positive, with a consensus “Moderate Buy” rating and a $97.56 target price, although the stock was trading near its 52-week high at $106.78.

American Capital Management Inc. acquired a new stake in Haemonetics Corporation (NYSE:HAE - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 66,915 shares of the medical instruments supplier's stock, valued at approximately $5,019,000. American Capital Management Inc. owned about 0.15% of Haemonetics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Kemnay Advisory Services Inc. purchased a new position in shares of Haemonetics during the 4th quarter valued at approximately $26,000. Leonteq Securities AG bought a new stake in shares of Haemonetics in the fourth quarter worth $30,000. EverSource Wealth Advisors LLC increased its stake in shares of Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier's stock worth $31,000 after buying an additional 396 shares during the last quarter. Kestra Advisory Services LLC acquired a new stake in Haemonetics in the fourth quarter valued at $34,000. Finally, Kelleher Financial Advisors acquired a new stake in Haemonetics in the second quarter valued at $38,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Price Performance

HAE opened at $106.78 on Thursday. The firm has a market cap of $4.86 billion, a price-to-earnings ratio of 52.34, a price-to-earnings-growth ratio of 2.17 and a beta of 0.52. Haemonetics Corporation has a fifty-two week low of $47.31 and a fifty-two week high of $109.57. The company's 50-day moving average price is $83.68 and its 200 day moving average price is $69.40. The company has a quick ratio of 1.91, a current ratio of 3.08 and a debt-to-equity ratio of 1.40.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.06. The firm had revenue of $339.38 million for the quarter, compared to analysts' expectations of $327.86 million. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. Haemonetics's revenue was up 5.5% on a year-over-year basis. During the same quarter last year, the company posted $1.10 earnings per share. As a group, sell-side analysts expect that Haemonetics Corporation will post 5.29 earnings per share for the current year.

Wall Street Analyst Weigh In

HAE has been the subject of several recent analyst reports. Weiss Ratings raised shares of Haemonetics from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday, August 11th. BTIG Research upped their target price on shares of Haemonetics from $96.00 to $110.00 and gave the company a "buy" rating in a research note on Tuesday, August 18th. Barrington Research lifted their price target on Haemonetics from $95.00 to $118.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 19th. Mizuho lifted their price target on Haemonetics from $85.00 to $90.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 15th. Finally, Bank of America raised Haemonetics from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $72.00 to $80.00 in a report on Friday, May 22nd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $97.56.

Trending Headlines about Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Zacks raised its FY2027 EPS estimate to $5.27 from $5.20, increased Q4 2027 to $1.46 from $1.42, and lifted Q4 2028 to $1.46 from $1.41.
• Positive Sentiment: Longer-term projections also improved modestly: Q1 2029 EPS rose to $1.41 from $1.33, while FY2029 increased to $6.20 from $6.19. These changes suggest some confidence in Haemonetics’ longer-term earnings growth.
• Neutral Sentiment: The overall revision pattern is mixed, with increases in some later-period estimates offset by reductions in other quarters. Zacks’ FY2028 forecast is now $5.67, and its FY2027 estimate of $5.27 remains close to the $5.28 current-year consensus.
• Negative Sentiment: Zacks lowered several estimates, including Q2 2027 EPS to $1.30 from $1.32, Q3 2027 to $1.36 from $1.37, Q1 2028 to $1.27 from $1.31, Q2 2028 to $1.44 from $1.45, Q3 2028 to $1.50 from $1.52, and FY2028 to $5.67 from $5.69.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source